- Home
- CURI vs FHTX Comparison
CURI vs FHTX Comparison
Compare CURI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURI | FHTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0M | 111.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CURI | FHTX |
|---|---|---|
| Price | $2.85 | $2.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $5.33 | $4.17 |
| AVG Volume (30 Days) | 479.8K | ★ 1.2M |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | ★ 11.81% | N/A |
| EPS Growth | ★ 54.17 | 25.32 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $78,043,000.00 | $30,909,000.00 |
| Revenue This Year | $10.59 | N/A |
| Revenue Next Year | $12.05 | $15.98 |
| P/E Ratio | $23.96 | ★ N/A |
| Revenue Growth | 9.52 | ★ 36.75 |
| 52 Week Low | $2.30 | $1.79 |
| 52 Week High | $5.10 | $7.61 |
Technical Indicators
Market Signals| Indicator | CURI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 25.12 |
| Support Level | $2.81 | $1.79 |
| Resistance Level | $2.97 | $5.27 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 71.95 | 61.43 |
Price Performance
Historical ComparisonAbout CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.